A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PHASE 2/3 STUDY OF FICERAFUSP ALFA (BCA101) OR PLACEBO IN COMBINATION WITH PEMBROLIZUMAB FOR FIRST LINE TREATMENT OF PD-L1-POSITIVE, RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA

Registry ID

BCA101X301

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE2

Study type

INTERVENTIONAL

Sponsor

BICARA THERAPEUTICS

Start date

2025-08-13

Last update

2025-01-24

Conditions

• CARCINOMA OF THE HEAD AND NECK

Related clinical trials

• A RANDOMIZED, PHASE 2, OPEN-LABEL, MULTI-ARM STUDY OF TISLELIZUMAB IN COMBINATION WITH INVESTIGATIONAL AGENTS AS FIRST-LINE TREATMENT IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
• INTRATYMPANIC N-ACETYLCYSTEINE (NAC) INJECTIONS FOR PREVENTION OF CISPLATIN-INDUCED OTOTOXICITY IN HEAD AND NECK CANCER PATIENTS: A MULTI-CENTRE PHASE II RANDOMIZED CONTROLLED TRIAL.
• "A PHASE II, RANDOMIZED, OPEN-LABEL, MULTI-CENTER, GLOBAL STUDY OF MEDI4736 MONOTHERAPY, TREMELIMUMAB MONOTHERAPY, AND MEDI4736 IN COMBINATION WITH TREMELIMUMAB IN PATIENTS WITH RECURRENT OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK (SCCHN)."
• A PHASE 3 CLINICAL TRIAL OF PEMBROLIZUMAB (MK-3475) IN FIRST LINE TREATMENT OF RECURRENT/METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
• RANDOMIZED CONTROLLED TRIAL TO TEST THE EFFICACY OF TRANS-TYMPANIC INJECTIONS OF A SODIUM THIOSULFATE GEL TO PREVENT CISPLATIN-INDUCED OTOTOXICITY IN PATIENTS WITH HEAD AND NECK CANCER

View on source registry